Intradermal immunization using coated microneedles containing an immunoadjuvant

Vaccine

Volumn 30, Issue 29, 2012, Pages 4355-4360

  Andrianov, Alexander K ^a   Mutwiri, George ^b  

^a Apogee Technology Inc   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Immunoadjuvants; Intradermal immunization; Microneedle technology; Polyphosphazenes; Vaccines

Indexed keywords

CARBOXYMETHYLCELLULOSE; HEPATITIS B SURFACE ANTIGEN; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; POLYPHOSPHAZENE MACROMOLECULAR IMMUNOADJUVANT; ROTAVIRUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CHOLERA; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS A H5N1; MINIMALLY INVASIVE PROCEDURE; NONHUMAN; POLYPHOSPHAZENE MICRONEEDLE; PRIORITY JOURNAL; REVIEW; ROTAVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNIZATION; INJECTIONS, INTRADERMAL; MICROTECHNOLOGY; NEEDLES; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; VACCINES;

EID: 84861994663     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.062     Document Type: Review

References (70)

1. Prausnitz M.R., Mikszta J.A., Cormier M., Andrianov A.K. Microneedle-based vaccines. Vaccines for pandemic influenza. Current topics in microbiology and immunology 2009, vol. 333:369-393. Springer.
2. Larregina A.T., Falo L.D. Changing paradigms in cutaneous immunology: adapting with dendritic cells. The Journal of Investigative Dermatology 2004, 124(1):1-12.
3. Petrovsky N., Heinzel S., Honda Y., Lyons A.B. New-age vaccine adjuvants: friend or foe? 2007, New-Age.
4. Bowersock T.L., Martin S. Vaccine delivery to animals. Advanced Drug Delivery Reviews 1999, 38(July (2)):167-194.
5. Singh M., O'Hagan D.T. Recent advances in veterinary vaccine adjuvants. International Journal for Parasitology 2003, 33(May (5-6)):469-478.
6. Grubhofer N.A. Vaccine adjuvants revisited. Open Veterinary Science Journal 2008, 2:63-67.
7. Jones K.S. Biomaterials as vaccine adjuvants. Biotechnology Progress 2008, 24(4):807-814.
8. Tamber H., Johansen P., Merkle H.P., Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Advanced Drug Delivery Reviews 2005, 57(3):357-376.
9. Kensil C.R., Mo A.X., Truneh A. Current vaccine adjuvants: an overview of a diverse class. Frontiers in Bioscience 2004, 9:2972-2988.
10. Kabanov A.V. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Advanced Drug Delivery Reviews 2006, 58(15):1597-1621.
11. Kabanov V.A. From synthetic polyelectrolytes to polymer-subunit vaccines. Pure and Applied Chemistry 2004, 76(9):1659-1677.
12. Dyakonova V.A, Dambaeva S.V., Pinegin B.V., Khaitov R.M. Study of interaction between the polyoxidonium immunomodulator and the human immune system cells. International Immunopharmacology 2004, 4(13):1615-1623.
13. Andrianov A.K. Polyphosphazenes as vaccine delivery systems: state of development and perspectives. Polyphosphazene for biomedical applications 2009, 47-63. John Wiley & Sons, Hoboken, New Jersey. A.K. Andrianov (Ed.).
14. Andrianov A.K., Marin A., Roberts B.E. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 2005, 6(3):1375-1379.
15. Arora A., Prausnitz M.R., Mitragotri S. Micro-scale devices for transdermal drug delivery. International Journal of Pharmaceutics 2008, 364(2):227-236.
16. Prausnitz M.R., Langer R. Transdermal drug delivery. Nature Biotechnology 2008, 26(11):1261-1268.
17. Kim Y.C. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. Journal of Infectious Diseases 2010, 201:190-198.
18. Kim Y.C., Quan F.S., Compans R.W., Kang S.M., Prausnitz M.R. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS Pharmaceutical Science and Technology 2010, 1-9.
19. Kim Y.C., Quan F.S., Compans R.W., Kang S.M., Prausnitz M.R. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. Journal of Controlled Release 2010, 142(2):187-195.
20. Zhu Q. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:7968-7973.
21. Kim Y.C., Quan F.S., Yoo D.G., Compans R.W., Kang S.M., Prausnitz M.R. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009, 27(49):6932-6938.
22. Koutsonanos D.G. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE 2009, 4:e4773.
23. Andrianov A.K., DeCollibus D.P., Gillis H.A., Kha H.H., Marin A., Prausnitz M.R., et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(November (45)):18936-18941.
24. Vaccine adjuvants and delivery systems 2006, Wiley-Interscience, Hoboken, NJ. M. Singh (Ed.).
25. Vogelbruch M., Nuss B., Korner M., Kapp A., Kiehl P., Bohm W. Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 2000, 55(9):883-887.
26. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(20):10833-10837.
27. McGowen A.L., Hale L.P., Shelburne C.P., Abraham S.N., Staats H.F. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 2009, 27(27):3544-3552.
28. ®). Vaccine 2000, 18(11-12):1059-1066.
29. Baldwin S.L., Bertholet S., Kahn M., Zharkikh I., Ireton G.C., Vedvick T.S., et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009, 27(23):3063-3071.
30. Disis M.L., Bernhard H., Shiota F.M., Hand S.L., Gralow J.R., Huseby E.S., et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996, 88(1):202-210.
31. Huang J., D'Souza A.J., Alarcon J.B., Mikszta J.A., Ford B.M., Ferriter M.S., et al. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clinical and Vaccine Immunology 2009, 16(5):719-725.
32. Mikszta J.A, Sullivan V.J., Dean C., Waterston A.M., Alarcon J.B., Dekker Iii J.P., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. Journal of Infectious Diseases 2005, 191(2):278-288.
33. Ding Z., Van Riet E., Romeijn S., Kersten G.F.A., Jiskoot W., Bouwstra J.A. Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharmaceutical Research 2009, 26(7):1635-1643.
34. Bal S.M., Ding Z., Kersten G.F.A., Jiskoot W., Bouwstra J.A. Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharmaceutical Research 2010, 27(9):1-11.
35. Matyas G.R., Friedlander A.M., Glenn G.M., Little S., Yu J., Alving C.R. Needle-free skin patch vaccination method for anthrax. Infection and Immunity 2004, 72(2):1181-1183.
36. Kenney R.T, Yu J., Guebre-Xabier M., Frech S.A., Lambert A., Heller B.A., et al. Induction of protective immunity against lethal anthrax challenge with a patch. Journal of Infectious Diseases 2004, 190(4):774-782.
37. Frech S.A., Kenney R.T., Spyr C.A., Lazar H., Viret J.F., Herzog C., et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005, 23(7):946-950.
38. Tierney R., Beignon A.S., Rappuoli R., Muller S., Sesardic D., Partidos C.D. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. Journal of Infectious Diseases 2003, 188(5):753-758.
39. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nature Medicine 2000, 6(12):1403-1406.
40. Guerena-Burgueno F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infection and Immunity 2002, 70(4):1874-1880.
41. Cui Z., Baizer L., Mumper R.J. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. Journal of Biotechnology 2003, 102(2):105-115.
42. Zuber A.K., Bråve A., Engström G., Zuber B., Ljungberg K., Fredriksson M., et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 2004, 22(13-14):1791-1798.
43. Zhang L., Widera G., Rabussay D. Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant. Bioelectrochemistry 2004, 63(1-2):369-373.
44. ® microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharmaceutical Research 2002, 19(1):63-70.
45. Andrianov A.K., Langer R. Polyphosphazenes for biology and medicine: current status and future prospects. Polyphosphazenes for biomedical applications 2009, 3-13. John Wiley & Sons, Hoboken, NJ. A.K. Andrianov (Ed.).
46. Payne L.G., Jenkins S.A., Andrianov A., Roberts B.E. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharmaceutical Biotechnology 1995, 6:473-493.
47. Payne L.G., Jenkins S.A., Andrianov A.K., Roberts B.E. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Vaccine design 1995, 473-493. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
48. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 1998, 16(1):92-98.
49. McNeal M.M., Rae M.N., Ward R.L. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 1999, 17(11-12):1573-1580.
50. Wu J.Y., Wade W.F., Taylor R.K. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infection and Immunity 2001, 69(12):7695-7702.
51. Lu Y., Salvato M.S., Pauza C.D., Li J., Sodroski J., Manson K., et al. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996, 12(2):99-106.
52. Mutwiri G., Benjamin P., Soita H., Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 2008, 26(22):2680-2688.
53. Mutwiri G., Benjamin P., Soita H., Townsend H., Yost R., Roberts B., et al. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 2007, 25(7):1204-1213.
54. Andrianov A.K., Decollibus D.P., Marin A., Webb A., Griffin Y., Webby R.J. PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies. Journal of Pharmaceutical Sciences 2011, 100(4):1436-1443.
55. Andrianov A.K., Svirkin Y.Y., LeGolvan M.P. Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 2004, 5(5):1999-2006.
56. Andrianov A.K., Chen J., LeGolvan M.P. Poly(dichlorophosphazene) as a precursor for biologically active polyphosphazenes: synthesis, characterization, and stabilization. Macromolecules 2004, 37(2):414-420.
57. Ison M.G., Mills J., Openshaw P., Zambon M., Osterhaus A., Hayden F. Current research on respiratory viral infections: fourth international symposium. Antiviral Research 2002, 55(2):227-278.
58. Payne L.G., Van Nest G., Barchfeld G.L., Siber G.R., Gupta R.K., Jenkins S.A. PCPP as a parenteral adjuvant for diverse antigens. Developments in Biological Standardization 1998, 92:79-87.
59. Eng N.F., Garlapati S., Lai K., Gerdts V., Mutwiri G. Polyphoaphazenes enhance mucosal and sustemic immune responses in mice immunized intranasally with influenza antigens. The Open Vaccine Journal 2009, 2:134-143.
60. Eng N.F., Garlapati S., Gerdts V., Babiuk L.A., Mutwiri G.K. PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens. Journal of Immune Based Therapies and Vaccines 2010, 8:4.
61. Johansson E., Istrate C., Charpilienne A., Cohen J., Hinkula J., Poncet D., et al. Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles. Vaccine 2008, 26(6):778-785.
62. Andrianov A.K., Marin A., Chen J. Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene]. Biomacromolecules 2006, 7(1):394-399.
63. Andrianov A.K., Sargent J.R., Sule S.S., Le Golvan M.P., Woods A.L., Jenkins S.A., et al. Synthesis, physico-chemical properties and immunoadjuvant activity of water-soluble phosphazene polyacids. Journal of Bioactive and Compatible Polymers 1998, 13(4):243-256.
64. Constant S.L, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annual Review of Immunology 1997, 15:297-322.
65. DeCollibus D.P., Marin A., Andrianov A.K. Effect of environmental factors on hydrolytic degradation of water-soluble polyphosphazene polyelectrolyte in aqueous solutions. Biomacromolecules 2010, 487-492.
66. Marin A., DeCollibus D.P., Andrianov A.K. Protein stabilization in aqueous solutions of polyphosphazene polyelectrolyte and non-ionic surfactants. Biomacromolecules 2010, 11(9):2268-2273.
67. Quan F.-S., Kim Y.-C., Yoo D.-G., Compans R.W., Prausnitz M.R., Kang S.-M. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS ONE 2009, 4(9):e7152.
68. Andrianov A., Marin A., DeCollibus D. Microneedles with intrinsic immunoadjuvant properties: microfabrication protein stability, and modulated release. Pharmaceutical Research 2011, 28(1):58-65.
69. Heinig K., Vogt C. Determination of Triton X-100 in influenza vaccine by high-performance liquid chromatography and capillary electrophoresis. Analytical and Bioanalytical Chemistry 1997, 359(2):202-206.
70. Monteiro-Riviere N.A Comparative anatomy, physiology and biochemistry of mammalian skin. Dermal and ocular toxicology: fundamentals and methods 1991, 3-71. CRC Press, Boca Raton, FL. D. Hobson (Ed.).